This compound is a pharmaceutical raw material used as an oral anti-diabetic DPP-4 inhibitor. It is a small-molecule active pharmaceutical ingredient with a complex structure containing aromatic rings and polar functional groups, suitable for use in research and pharmaceutical manufacturing.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1108732-05-3
(S)-Alogliptin Benzoate Salt
pharmaceutical raw material
Entrectinib
pharmaceutical raw material
N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]Benzamide
pharmaceutical raw material
Oxalic acid--2-hydroxy-N-(3-{3-[(piperidin-1-yl)methyl]phenoxy}propyl)acetamide (1/1)
pharmaceutical raw material
PUBCHEM_71308369
pharmaceutical raw material
2-({6-[(3R)-3-Aminopiperidin-1-yl]-3-(²H₃)methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
pharmaceutical intermediate
Alogliptin (13CD3)
pharmaceutical raw material
Alogliptin
pharmaceutical raw material
2-[[6-[(3S)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
ZSBOMTDTBDDKMP-HNNXBMFYSA-N
CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@@H](C3)N